Article

Massive Bio Onboards Over 100,000 Cancer Patients

Massive Bio announced that the company exceeded its goal to onboard 100,000 cancer patients in its platform by the end of 2022. The Massive Bio platform matches cancer patients with relevant clinical trials using AI.

Read more about the platform and its enrollment here.

.


Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Related Content
Dynavax Technologies’ Investigational Shingles Vaccine Achieves Complete Antibody Response in Phase I/II Shingles Trial
August 23rd 2025

Dynavax Technologies’ Investigational Shingles Vaccine Achieves Complete Antibody Response in Phase I/II Shingles Trial

Don Tracy, Associate Editor
ACT Brief Episode 5: How Digital Twins and AI Are Reshaping Clinical Trials
August 23rd 2025

ACT Brief Episode 5: How Digital Twins and AI Are Reshaping Clinical Trials

Andy Studna, Senior Editor
© Production Perig - © Production Perig - stock.adobe.com
August 23rd 2025

Phase II Trial Launches of Anktiva in Long COVID Patients

Andy Studna, Senior Editor
ACT Brief Episode 4: New Data on Trial Delays, Hybrid Payment Models, and Managing Complexity
August 23rd 2025

ACT Brief Episode 4: New Data on Trial Delays, Hybrid Payment Models, and Managing Complexity

Andy Studna, Senior Editor
© Pixel-Shot - © Pixel-Shot - stock.adobe.com
August 23rd 2025

NCX 470 Meets Phase III Goal in Glaucoma With Strong Intraocular Pressure Reductions

Andy Studna, Senior Editor
FDA Lifts Clinical Hold on Rocket Pharmaceuticals’ Phase II Novel Investigative Gene Therapy Trial for Danon Disease
August 23rd 2025

FDA Lifts Clinical Hold on Rocket Pharmaceuticals’ Phase II Novel Investigative Gene Therapy Trial for Danon Disease

Don Tracy, Associate Editor
© 2025 MJH Life Sciences

All rights reserved.